Literature DB >> 12188412

Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.

Prasert Lertsanguansinchai1, Taywin Chottetanaprasith, Kris Chatamra, Pichet Sampatanukul, Pongsak Wannakrairot, Prayuth Rojpornpradit, Kanjana Shotelersuk, Chawalit Lertbutsayanukul, Darunee Boonjunwetwat, Laddawan Vajragupta.   

Abstract

A retrospective review was performed on 576 patients who have been diagnosed breast cancer and referred to Division of Radiation Therapy, Department of Radiology, King Chulalongkorn Memorial Hospital between January 1995-September 2001. There were three hundred ninety nine cases of invasive breast cancer that available for estrogen (ER) and/or progesterone (PR) receptor status. The mean and median age in our study were 49.6 year and 49.0 year respectively. About 60.9 per cent of the patients were pre and peri-menopause and 37.8 per cent were post-menopause. Most of the histological cell type were invasive ductal carcinoma which comprised of 92.7 per cent. Histologic grading were nearly equal for moderately and poorly differentiated grade: 43.66 per cent and 40.66 per cent. The results of our study showed 53.4 per cent of 399 patients had ER positive and 42.1 per cent of 380 patients had PR positive. The proportion of ER+PR+, ER+PR-, ER-PR+, and ER-PR- were 36.31 per cent, 15.53 per cent, 5.79 per cent and 42.37 per cent respectively. Older age and post-menopause women had higher ER+. While patients with increase tumor size, poorly differentiated grading, increase positivity of axillary lymph nodes and higher stage have more chance of ER negative and PR negative.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12188412

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  5 in total

1.  Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.

Authors:  Maher A Sughayer; Maha M Al-Khawaja; Suleiman Massarweh; Mahmoud Al-Masri
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

2.  Profile of breast cancer in a group of women in a developing country in South Asia: is there a difference?

Authors:  Menaka D S Lokuhetty; Gayani G Ranaweera; Manarangi D M Wijeratne; Kumudu H Wickramasinghe; Abdul H Sheriffdeen
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

3.  Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer.

Authors:  Doonyapat Sa-Nguanraksa; Thitikon Krisorakun; Wanee Pongthong; Pornchai O-Charoenrat
Journal:  Mol Clin Oncol       Date:  2019-08-20

4.  Pathum Raksa Project: Addressing Disparity in Breast Cancer Care Through National Innovation in Thailand.

Authors:  Supinda Koonmee; Ongart Somintara; Piyapharom Intarawichian; Chaiwat Aphivatanasiri; Sakkarn Sangkhamanon; Suphawat Laohawiriyakamol; Rujira Panawattanakul; Phanchanut Mahantassanapong; Chayanoot Rattadilok; Piyarat Jeeravongpanich; Wilart Krongyute; Krisada Prachumrasee; Reza Alaghehbandan
Journal:  Cancer Manag Res       Date:  2021-11-23       Impact factor: 3.989

5.  Systematic review of breast cancer biology in developing countries (part 2): asian subcontinent and South East Asia.

Authors:  Riyaz Bhikoo; Sanket Srinivasa; Tzu-Chieh Yu; David Moss; Andrew G Hill
Journal:  Cancers (Basel)       Date:  2011-05-13       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.